Lion Biotechnologies Company Profile (NASDAQ:IOVA)

About Lion Biotechnologies (NASDAQ:IOVA)

Lion Biotechnologies logoIovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Diagnostics & Testing
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IOVA
  • CUSIP: N/A
  • Web:
  • Market Cap: $482.69 million
  • Outstanding Shares: 62,687,000
Average Prices:
  • 50 Day Moving Avg: $5.61
  • 200 Day Moving Avg: $6.42
  • 52 Week Range: $4.45 - $8.61
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.24
  • P/E Growth: 0.00
  • Return on Equity: -18.59%
  • Return on Assets: -17.95%
  • Current Ratio: 15.29%
  • Quick Ratio: 15.29%
  • Average Volume: 360,975 shs.
  • Beta: 4.5

Frequently Asked Questions for Lion Biotechnologies (NASDAQ:IOVA)

What is Lion Biotechnologies' stock symbol?

Lion Biotechnologies trades on the NASDAQ under the ticker symbol "IOVA."

How were Lion Biotechnologies' earnings last quarter?

Lion Biotechnologies, Inc. (NASDAQ:IOVA) announced its earnings results on Monday, May, 1st. The company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.05. View Lion Biotechnologies' Earnings History.

Where is Lion Biotechnologies' stock going? Where will Lion Biotechnologies' stock price be in 2017?

9 brokers have issued twelve-month price objectives for Lion Biotechnologies' stock. Their forecasts range from $11.00 to $20.00. On average, they expect Lion Biotechnologies' stock price to reach $14.86 in the next year. View Analyst Ratings for Lion Biotechnologies.

What are analysts saying about Lion Biotechnologies stock?

Here are some recent quotes from research analysts about Lion Biotechnologies stock:

  • 1. Cowen and Company analysts commented, "IOVA reported that the first patient in LN-145’s Phase II cervical cancer study has been." (8/16/2017)
  • 2. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (8/3/2017)
  • 3. HC Wainwright analysts commented, "We project that one or more of these patients who achieved early PRs could transform to CRs with more follow up time as the infused TILs continue to act." (6/7/2017)
  • 4. Jefferies Group LLC analysts commented, "LBIO reported 4Q16 financials and provided a pipeline update. LN-144 is on track with enrollment with data expected in 2017 at a medical congress. LBIO is also planning for add'l clinical trials in 2017 and has initiated head and neck indication with the cervical indication to initiate shortly. We think LBIO is making reasonable progress and look to the first LN-144 data readout for more details." (3/8/2017)

Who are some of Lion Biotechnologies' key competitors?

Who are Lion Biotechnologies' key executives?

Lion Biotechnologies' management team includes the folowing people:

  • Wayne Rothbaum, Interim Chairman of the Board
  • Maria Fardis Ph.D., President, Chief Executive Officer
  • Gregory T. Schiffman, Chief Financial Officer
  • James G. Bender Ph.D., Vice President
  • Iain D Dukes, Director
  • Ryan D. Maynard, Director
  • Sanford J. Hillsberg J.D., Independent Director
  • Merrill A. McPeak USAF, Independent Director
  • Jay Venkatesan M.D., Independent Director

Who owns Lion Biotechnologies stock?

Lion Biotechnologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (8.26%), FMR LLC (4.55%), Victory Capital Management Inc. (4.15%), Broadfin Capital LLC (3.63%), Vanguard Group Inc. (3.52%) and Frazier Management LLC (3.49%). View Institutional Ownership Trends for Lion Biotechnologies.

Who bought Lion Biotechnologies stock? Who is buying Lion Biotechnologies stock?

Lion Biotechnologies' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, Victory Capital Management Inc., Broadfin Capital LLC, Vanguard Group Inc., Frazier Management LLC, JPMorgan Chase & Co. and State Street Corp. View Insider Buying and Selling for Lion Biotechnologies.

How do I buy Lion Biotechnologies stock?

Shares of Lion Biotechnologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lion Biotechnologies' stock price today?

One share of Lion Biotechnologies stock can currently be purchased for approximately $7.70.

MarketBeat Community Rating for Lion Biotechnologies (NASDAQ IOVA)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  272
MarketBeat's community ratings are surveys of what our community members think about Lion Biotechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Lion Biotechnologies (NASDAQ:IOVA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.86 (92.95% upside)

Analysts' Ratings History for Lion Biotechnologies (NASDAQ:IOVA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/13/2017HC WainwrightReiterated RatingBuy$16.00HighView Rating Details
9/7/2017Chardan CapitalReiterated RatingBuyHighView Rating Details
9/11/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$13.00LowView Rating Details
9/5/2017Jefferies Group LLCReiterated RatingBuy$11.00HighView Rating Details
8/16/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
5/18/2017FBR & CoReiterated RatingBuyHighView Rating Details
5/10/2017Rodman & RenshawInitiated CoverageBuy -> Buy$13.00LowView Rating Details
3/17/2017Wells Fargo & CompanyInitiated CoverageOutperform -> OutperformHighView Rating Details
3/8/2017Roth CapitalSet Price TargetBuy$14.00LowView Rating Details
6/6/2016SunTrust Banks, Inc.DowngradeBuy -> Neutral$37.00 -> $30.50N/AView Rating Details
12/3/2015Piper Jaffray CompaniesReiterated RatingBuy$21.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Lion Biotechnologies (NASDAQ:IOVA)
Earnings by Quarter for Lion Biotechnologies (NASDAQ:IOVA)
Earnings History by Quarter for Lion Biotechnologies (NASDAQ IOVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($0.28)($0.33)ViewListenView Earnings Details
3/7/2017Q4 2016($0.25)($0.25)ViewListenView Earnings Details
11/4/2016Q316($0.22)($0.32)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.19)($0.23)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.16)($0.14)ViewN/AView Earnings Details
3/10/2016Q4($0.20)($0.20)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.20)($0.16)ViewN/AView Earnings Details
8/10/2015Q2 2015($0.17)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Lion Biotechnologies (NASDAQ:IOVA)
Current Year EPS Consensus Estimate: $-1.42 EPS
Next Year EPS Consensus Estimate: $-1.47 EPS


Dividend History for Lion Biotechnologies (NASDAQ:IOVA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Lion Biotechnologies (NASDAQ:IOVA)
Insider Ownership Percentage: 13.20%
Institutional Ownership Percentage: 76.00%
Insider Trades by Quarter for Lion Biotechnologies (NASDAQ:IOVA)
Institutional Ownership by Quarter for Lion Biotechnologies (NASDAQ:IOVA)
Insider Trades by Quarter for Lion Biotechnologies (NASDAQ:IOVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Sanford HillsbergDirectorSell54,000$8.95$483,300.00View SEC Filing  
8/22/2016Sanford HillsbergDirectorSell54,000$9.11$491,940.00View SEC Filing  
9/8/2015Sanford HillsbergDirectorSell32,500$6.99$227,175.00View SEC Filing  
5/6/2015Sanford HillsbergDirectorSell50,000$10.00$500,000.00View SEC Filing  
11/5/2013Manish SinghCEOBuy125,000$2.00$250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Lion Biotechnologies (NASDAQ:IOVA)
Latest Headlines for Lion Biotechnologies (NASDAQ:IOVA)
DateHeadline logoLion Biotechnologies, Inc. (IOVA) Given Average Recommendation of "Buy" by Brokerages - September 24 at 4:34 AM logo Analysts Expect Lion Biotechnologies, Inc. (IOVA) to Post -$0.35 EPS - September 23 at 2:32 PM logoIovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock - September 20 at 9:24 PM logoIovance Biotherapeutics, Inc. Announces Public Offering of Common Stock - September 19 at 8:01 PM logoLion Equity Partners Completes Acquisition of Vivabox USA from Sodexo - September 18 at 7:25 PM logoIovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer - September 14 at 6:31 AM logoLion Biotechnologies' (IOVA) "Buy" Rating Reaffirmed at Chardan Capital - September 13 at 7:18 PM logoLion Biotechnologies, Inc. (IOVA) Earns "Buy" Rating from HC Wainwright - September 13 at 8:04 AM logoLion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target at Oppenheimer Holdings, Inc. - September 11 at 8:58 PM logoIovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management - September 11 at 8:40 PM logoHead-To-Head Review: Digiliti Money (DGLT) vs. Lion Biotechnologies (IOVA) - September 8 at 12:30 PM logoIovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center - September 7 at 8:16 PM logoIovance Biotherapeutics to Present at Two Upcoming September Conferences - September 5 at 4:43 PM logoZacks: Brokerages Expect Lion Biotechnologies, Inc. (IOVA) to Post -$0.35 Earnings Per Share - September 4 at 6:20 PM logoInVitae Corp (NVTA) vs. Lion Biotechnologies (IOVA) Head-To-Head Analysis - September 3 at 6:40 PM logoChardan Capital Reaffirms "Buy" Rating for Lion Biotechnologies, Inc. (IOVA) - September 1 at 12:56 PM logoLion Biotechnologies, Inc. (IOVA) Given "Buy" Rating at HC Wainwright - August 31 at 10:04 PM logoIovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications - August 31 at 7:58 PM logoIovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma - August 31 at 7:58 PM logoLion Biotechnologies, Inc. (IOVA) Receives Consensus Recommendation of "Buy" from Brokerages - August 30 at 4:30 AM logoDigiliti Money (DGLT) vs. Lion Biotechnologies (IOVA) Head to Head Contrast - August 23 at 10:22 PM logoHead-To-Head Contrast: InVitae Corp (NVTA) versus Lion Biotechnologies (IOVA) - August 20 at 4:22 PM logoLion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target by Oppenheimer Holdings, Inc. Analysts - August 19 at 11:32 PM logoLion Biotechnologies (IOVA) and InVitae Corp (NVTA) Head-To-Head Survey - August 18 at 2:26 PM logoIovance Biotherapeutics Inc (IOVA) PT Set at $16.00 by HC Wainwright - August 16 at 8:26 PM logoIovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer - August 16 at 4:43 PM logoIovance Biotherapeutics Inc (IOVA) Stock Rating Reaffirmed by Cowen and Company - August 16 at 3:12 PM logoLion Biotechnologies (IOVA) & Veracyte (VCYT) Critical Analysis - August 13 at 8:10 PM logoHead to Head Comparison: Lion Biotechnologies (IOVA) vs. Digiliti Money (DGLT) - August 11 at 12:14 AM logoAnalyzing Lion Biotechnologies (IOVA) and Veracyte (VCYT) - August 9 at 10:50 PM logoIovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer - August 8 at 7:36 PM logoLion Biotechnologies, Inc. (IOVA) Now Covered by Oppenheimer Holdings, Inc. - August 6 at 8:28 PM logoLion Biotechnologies, Inc. (IOVA) Given Consensus Rating of "Buy" by Brokerages - August 5 at 7:09 AM logoLion Biotechnologies, Inc. (NASDAQ:IOVA) Rating Lowered to Hold at Zacks Investment Research - August 3 at 11:38 PM logoIovance Biotherapeutics Reports Second Quarter 2017 Financial Results - August 1 at 8:35 PM logoLion Biotechnologies reports 2Q loss - August 1 at 8:35 PM logoIovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017 - July 25 at 8:17 PM logoLion Biotechnologies (NASDAQ:IOVA) versus Veracyte (VCYT) Head to Head Comparison - July 21 at 12:07 AM logoLion Biotechnologies, Inc. (NASDAQ:IOVA) Upgraded by Zacks Investment Research to "Buy" - July 19 at 12:52 AM logoLion Biotechnologies, Inc. (NASDAQ:IOVA) Expected to Announce Earnings of -$0.34 Per Share - July 5 at 10:16 PM



Lion Biotechnologies (IOVA) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff